August 28, 2014 1:02 PM ET

Pharmaceuticals

Company Overview of Edge Therapeutics, Inc.

Company Overview

Edge Therapeutics, Inc., a hospital-focused biopharmaceutical company, designs and develops implantable technology for direct delivery of therapeutic compounds to the site of brain injury. Its drugs cover therapeutic areas, such as spontaneous brain hemorrhage, traumatic brain injuries, and brain surgeries. The company develops NimoGel and NimoVent to prevent delayed cerebral ischemia, a catastrophic delayed complication after subarachnoid hemorrhage. Its therapeutics are delivered to patients in the United States and internationally. The company was founded in 2009 and is based in New Providence, New Jersey.

139 South Street

Suite 102

New Providence, NJ 07974

United States

Founded in 2009

Phone:

800-208-3343

Fax:

800-208-3433

Key Executives for Edge Therapeutics, Inc.

Co-Founder
Chief Financial Officer
Age: 54
Chief Accounting and Operations Officer
Compensation as of Fiscal Year 2014.

Edge Therapeutics, Inc. Key Developments

Edge Therapeutics Initiates Enrollment of Second Cohort in Phase 1/2 NEWTON Study of EG-1962 for Improvement of Outcome after Ruptured Brain Aneurysm

Edge Therapeutics announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962. The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study is evaluating the safety, tolerability and pharmacokinetics of EG-1962 compared to the current standard of care, oral nimodipine, in patients with aneurysmal subarachnoid hemorrhage (aSAH). The company is also assessing patient functional outcomes at 30 and 90 days, which it believes will be indicative of the potential efficacy of EG-1962. EG-1962 is a novel polymeric nimodipine microparticle utilizing Edge's proprietary Precisa(TM) development platform and is being developed to improve patient outcome after aSAH, also commonly referred to as ruptured brain aneurysm.

Edge Therapeutics, Inc. Announces Opening of New Corporate Headquarters

Edge Therapeutics, Inc. announced that the company has opened its new corporate headquarters at 200 Connell Drive, Suite 1600, Berkeley Heights, New Jersey.

Edge Therapeutics Announces Executive Appointments

Edge Therapeutics announced the appointment and promotion of key executives to its senior management team to strengthen the Company's leadership. Herbert J. Faleck, D.O. has joined Edge as Chief Medical Officer; Andrew J. Einhorn as Chief Financial Officer; Alpaslan Yaman, Ph.D. as Vice President, Operations and Manufacturing, Gene Mack as Senior Director, Investor Relations, and William Shatynski as Senior Director, Financial Reporting and Controller. Additionally, Albert Marchio has been appointed to the expanded role of Chief Accounting and Operations Officer for the Company. Dr. Faleck, a pediatric neurologist, has more than 25 years of experience in clinical research. Prior to joining Edge, he was the Chief Medical Officer of Celgene Cellular Therapeutics where he led the clinical, medical, regulatory and organizational development for a key division of Celgene Corporation. Mr. Einhorn has more than 10 years of experience in the pharmaceutical industry in the development and execution of corporate strategy. Prior to joining Edge, he served as co-founder and Chief Financial Officer for three specialty pharmaceutical and therapeutics companies: Oceana Therapeutics, Inc., Esprit Pharma, and ESP Pharma, where he was involved in numerous financing, acquisition and licensing transactions across a variety of therapeutic areas and geographies, and played a key role in the ultimate sale of those companies to larger pharmaceutical companies. Prior to Edge, Mr. Mack was a Senior Biotechnology Analyst at Brean Capital and spent the majority of his career at Lazard Capital Markets. Prior to joining Edge, Mr. Shatynski was Senior Director and Controller at Insmed Inc. where he was responsible for internal and external financial reporting, Sarbanes-Oxley 404 compliance and SEC filings. Dr. Yaman has more than 28 years of biotech, pharmaceutical and medical device industry experience in sterile and non-sterile formulation development, process development and scale-up, validation, technology transfer and technical services with specific experience in sterile microparticle process design and scale-up. Dr. Yaman worked for Johnson & Johnson in Product Support/Technical Services and Schering Plough as Director, Pharmaceutical Technology Transfer and Global Technical Services.

Similar Private Companies By Industry

Company Name Region
GLG Pharma, LLC United States
InB: Hauser Pharmaceutical Services, Inc. United States
NanoVec, Inc. United States
Sirius Laboratories, Inc. United States
Cerep Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Edge Therapeutics, Inc., please visit www.edgetherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.